Can’t Let Go: HHS Seeks To Overturn US Court Decision Striking Down DTC Ad Rule
The appeal is in keeping with the President Trump’s plan to stay active on drug pricing initiatives so he can claim victory on a key campaign promise.
You may also be interested in...
Trump Administration addresses concerns that the rule violates the First Amendment and exceeds its statutory authority in the final rule, which is strongly opposed by biopharma.
DTC spending had shown an uptick in 2020 compared with 2019. Many advertisers are not, however, providing clear drug pricing information in their TV spots, despite some voluntary commitments to do so.
Proposal is more of a plan to make a plan, but Pharma should realize that time is running out on its existing policy strategies.